摘要
目的:探讨阿托伐他汀联合曲美他嗪对冠心病患者血脂、炎性因子水平及心功能的疗效。方法:选择138例冠心病患者为研究对象,按随机数字表法患者被均分为曲美他嗪组(在常规治疗基础上接受曲美他嗪治疗)和联合治疗组(在曲美他嗪组基础上加用阿托伐他汀)。观察比较两组治疗前后血脂:TC、TG、HDL-C、LDL-C,N末端B型利钠肽前体(NT-proBNP)、hsCRP、纤维蛋白原(Fg)水平,LVEF、LVEDd、左室后壁厚度(LVPWT)及6分钟步行距离(6MWD)变化。结果:与曲美他嗪组比较,联合治疗组治疗后TC[(5.13±0.94)mmol/L比(4.39±0.77)mmol/L]、TG[(2.10±0.72)mmol/L比(1.84±0.79)mmol/L]、LDL-C[(2.32±0.67)mmol/L比(1.91±0.65)mmol/L]、NT-proBNP[(293.60±28.17)pg/ml比(187.50±32.59)pg/ml]、hsCRP[(2.39±0.97)mg/L比(1.99±0.81)mg/L]、Fg[(4.45±0.44)g/L比(3.62±0.58)g/L]水平、LVEDd[(59.26±6.07)mm比(49.46±4.26)mm]和LVPWT[(11.02±1.11)mm比(10.02±1.23)mm]降低更显著;HDL-C[(1.31±0.23)mmol/L比(1.46±0.32)mmol/L]水平、LVEF[(41.29±7.05)%比(47.52±8.11)%]和6MWD[(330.46±86.63)m比(506.18±100.58)m]升高更显著,P<0.05或<0.01。结论:阿托伐他汀联合曲美他嗪治疗有助于控制冠心病患者血脂水平,降低炎性反应,改善心脏功能,效果显著。
Objective: To explore therapeutic effect of atorvastatin combined trimetazidine on blood lipids, inflammatory factors and cardiac function in patients with coronary heart disease (CHD). Methods: According to random number table,a total of 138 CHD patients were equally divided into trimetazidine group (received trimetazidine based on routine treatment) and combined treatment group (received atorvastatin based on Levels of blood lipid : TC,TG,HDL-C,LDL-C; N terminal pro-brain natriuretic peptide (NT-proBNP), hsCRP, fibrinogen (Fg),LVEF,LVEDd,left ventricular posterior wall thicknes (LVPWT) and 6min walking distance (6MWD) were observed and compared between two groups before and after treatment. Results: Compared with trmetazidine group after treatment,there were significant reductions in levels of TC [ (5. 13±0. 94) mmol/Lvs.(4. 39 ± 0. 77) mmol/L],TG [ (2. 10 ± 0. 72) mmol/Lvs. (1. 84 ± 0. 79) mmol/L],LDL-C [ (2. 32 ± 0. 67) mmolLvs. (1. 91 ± 0. 65) mmol/L], NT-proBNP [ (293. 60 ± 28. 17) pg/ml vs. (187. 50 ± 32. 59) p g /m l] , hsCRP [ (2. 39±0.97)mg/Lvs.(1.99±0.81)mg/L],F g [ ( 4 .4 5 ± 0 .4 4 ) g /L v s . ( 3 .6 2 ± 0 .5 8 ) g /L ], LV ED d [ (5 9 .2 6 ± 6 .0 7 )mm vs. (49. 46 土 4. 26) mm] and LVPWT [ ( 11. 02 土 1. 11) mm vs. (10. 02 ± 1. 23) m m ] ; and significant rise inHDL-C level [1 31 土 0. 23) mmol/L vs. 1 46 ± 0. 32) mmol/L],LVEF [(41. 29 ± 7. 05)% vs. (47. 52± 8. 11)%]and 6MWD [ (330. 46 ± 86.63) m vs. (506. 18 ± 100.58) m] in combined treatment group, P 〈 0. 05 or 〈0. 01. Conclusion: Atorvastatin combined trimetazidine is help to control blood lipid levels,reduce inflammatory reactions and improve heart function in patients with coronary heart disease,and the therapeutic effect is singnificant.
出处
《心血管康复医学杂志》
CAS
2016年第3期276-280,共5页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
冠心病
阿托伐他汀
曲美他嗪
Coronary disease
Atorvastatin
Trimetazidine